Key result
Elevated pretreatment or rising hs-cTnT during chemoradiation is linked to increased severe CAEs and mortality.
Why the study?
Cancer therapy-induced cardiotoxicities negatively affect quality of life and survival, prompting investigation into whether hs-cTnT could serve as a biomarker for early detection of cardiac adverse events after chemoradiation therapy for NSCLC.
Does high-sensitivity cardiac troponin T (hs-cTnT) predict cardiac adverse events and mortality in patients with NSCLC undergoing chemoradiation therapy?
Cohort (n=225)
Does high-sensitivity cardiac troponin T (hs-cTnT) predict cardiac adverse events and mortality in patients with NSCLC undergoing chemoradiation therapy?
Routine monitoring of hs-cTnT during chemoradiation therapy for NSCLC can identify patients at high risk for cardiotoxicity and mortality.
No takes yet. Share an insight, caveat, or question.
hs-cTnT elevation during CRT was associated with higher CAE and mortality risk; hypothesis-generating for serial monitoring in NSCLC.
Xu et al. (2021) conducted a cohort in Non-Small Cell Lung Cancer (NSCLC) (n=225). High-sensitivity cardiac troponin T (hs-cTnT) levels vs. Lower hs-cTnT levels was evaluated on Severe cardiac adverse events (CAEs) and mortality. Pretreatment hs-cTnT >10 ng/L or an increase of ≥5 ng/L during chemoradiation therapy were significantly associated with increased risks of severe cardiac adverse events and mortality.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: